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Abstract: Lifestyle changes, such as overeating and underexercising, can increase the risk of predia-
betes. Diabetes is one of the leading causes of atherosclerosis, and recently it became clear that the
pathophysiology of atherosclerosis progresses even before the onset of diabetic symptoms. In ad-
dition to changes in platelets and leukocytes in the hyperglycemic state and damage to vascular
endothelial cells, extracellular vesicles and microRNAs were found to be involved in the progression
of prediabetes atherosclerosis. This review discusses the cellular and molecular mechanisms of these
processes, with an intention to enable a comprehensive understanding of the pathophysiology of
prediabetes and atherosclerosis.
Keywords: prediabetes; atherosclerosis; metabolic syndrome; obesity; endothelial dysfunction;
exosome; microRNA
1. Introduction
Contrary to the common belief that atherosclerosis is a disease of the elderly, the
disease can begin surprisingly early, even before the age of 14 [1]. The modern age of
gourmet foods, overeating, and underexercising has caused many people to develop
metabolic syndromes that eventually lead to prediabetes and diabetes. Genetic factors
probably play a role in this process. The likelihood of developing diabetes increases in
subjects with a family history of diabetes [2]. Diabetes is one of the critical factors in the
development of atherosclerosis. This fact is even relevant to the pandemic of coronavirus
disease 2019 (COVID-19), as recent reports showed that patients with diabetes mellitus
(DM) and atherosclerosis are at a greater risk for severe COVID-19 complications [3].
Therefore, it is essential to understand the mechanism underlying the development of
atherosclerosis as diabetes progresses.
Numerous studies indicated that prediabetes can cause cardiovascular disease (CVD) [4,5].
Moreover, the burden of coronary atherosclerosis in prediabetic patients is more significant
than that in normal people. Notably, the burden of atherosclerosis appeared even before the
clinical manifestations of DM as seen in [4]. For example, lipid-rich plaques that congest
blood vessels were already found in coronary lesions in the prediabetic state [4,6]. In addi-
tion, inflammation and vasoconstriction, which promote atherosclerosis in the coronary
arteries, were observed in the prediabetic state [7,8]. Therefore, it is also meaningful to
discuss inflammation and the role of immune cells in the pathogenesis of prediabetic
atherosclerosis.
Moreover, it has become clear that the extracellular vesicles released from cells and mi-
croRNAs (miRNA) that regulate gene expression play important roles in the arteriosclerosis
progression in prediabetes. Here, we discuss these exciting new findings on the mechanism
of atherosclerosis in prediabetes to explore new ways of preventing the disease.
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2. The Effect of the Release of Inflammatory Factors Caused by Obesity on CVD
Atherosclerosis is a chronic inflammatory process within the arterial wall [9]. Atheroscle-
rosis is promoted when cholesterol-rich atherosclerotic Apo-B lipoproteins, such as low-
density lipoproteins (LDL), very-low-density lipoproteins, and intermediate-density lipopro-
teins, enter into the subendothelial space via the endothelial passage (transcytosis) and
accumulate in plasma [9]. The transcytosed Apo-B lipoproteins infiltrate macrophages and
T cells to interact with the arterial wall cells, activating the inflammatory response [9,10].
Inflammation caused by obesity may accelerate atherosclerosis [11]. Adipose tissue is crucial
in CVD caused by obesity [12]. In this situation, both fat cells and activated macrophages
from the adipose tissue can produce various cytokines [12] (see Figure 1). These cytokines
include adipokines induced by inflammation, such as leptin, adiponectin, tumor necrosis
factor-alpha (TNF-α), interleukin 1 (IL-1), and IL-6; coagulants, such as PAI-1; vasoactive
substances, such as leptin, angiotensinogen, and endothelin; and molecules such as FFA,
TNF-α, and resistin that may cause insulin resistance. Table 1 shows the blood levels of sev-
eral inflammatory factors associated with the development of atherosclerosis in prediabetes
and diabetes.
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1 to bind to IL-1R. The relative occupation rate of the IL-1R1–IL-1RAcP receptor complex 
for IL-1 agonist or IL-1Ra controls the activation of the inflammatory signal [15,16]. In the 
obese condition, these cytokines released into the adipose tissue’s circulatory system can 
stimulate the production of C-reactive protein in the liver [17]. The level of the thrombosis 
molecule PAI-1 also increases before the development of obesity, whereas the level of ad-
iponectin, which is only produced by fat cells, decreases [18]. Leptin is a crucial regulator 
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IL-1 si li i l es t e t e I IL-1 receptor (IL-1R/IL-1R1) that can heterodimerize
with t e IL-1R accessory protein (IL-1RAcP) [13,14]. IL-1 receptor antagonist (IL-1Ra) is
an anti-inflam atory cytokine that can compete with the proinflammatory cytokine IL-1
to bind to IL-1R. The relative occupation rate of the IL-1R1–IL-1R cP receptor co plex
for IL-1 agonist or IL-1Ra controls the activation of the infla atory signal [15,16]. In the
obese condition, these cytokines released into the adipose tissue’s circulatory syste can
stimulate the production of C-reactive protein in the liver [17]. The level of the thrombosis
molecule PAI-1 also increases before the development of obesity, whereas the level of
adiponectin, which is only produced by fat cells, decreases [18]. Leptin is a crucial regulator
of food intake and is a critical vasoactive substance produced by fat cells [19]. Other
molecules produced by fat cells, including prostaglandin, adiponectin, and resistin, can
influence metabolic function and lead to cardiovascular end-organ damage [20].
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Regarding the effect of obesity on the cardiovascular system, researchers have also
focused on the role of perivascular adipose tissue (PVAT). PVAT is an active endocrine
organ that anatomically wraps the blood vessels and plays an important role in the patho-
genesis of CVD. PVAT can secrete various adipokines, cytokines, and growth factors that
inhibit or stimulate CVD development [21,22] (Figure 1). Dysfunction of PVAT can cause
inflammation and oxidative stress and can decrease the production of vasoprotective
adipocyte-derived relaxation factors and paracrine factors, such as resistin and leptin, and
that of cytokines, such as IL-6 and TNF-α, and chemokines, such as RANTES and MCP-1
(also known as CCL5 and CCL2, respectively) [21]. These adipocyte-derived factors can
trigger and coordinate the infiltration of inflammatory cells, such as T cells, B cells, and NK
cells. Protective factors such as adiponectin can reduce the generation of NADPH oxidase
superoxide and promote the bioavailability of nitric oxide (NO) in the blood vessel wall.
Inflammatory molecules (such as IFN-γ or IL-17) can cause fibrosis in the endothelium,
vascular smooth muscle cells, and adventitia, leading to the induction of vascular oxidase
and eNOS dysfunction in cells [23,24]. These conditions lead to the occurrence of vascular
dysfunction caused by dysfunctional perivascular fat. These mechanisms play a critical
role in several CVDs, including atherosclerosis, hypertension, diabetes, and obesity [21,25].
Table 1. Comparison of the factors contribute to atherogenesis between prediabetes and diabetes.
Normal Prediabetes Diabetes Refs
Fasting glucose (mg/dL) 86.4 ± 8.6 93.4 ± 11 120.2 ± 19 [26]
HbA1c (%) 5.3 ± 0.2 6.0 ± 0.3 7.1 ± 0.5 [26]
Total cholesterol (mg/dL) 189–202 196–203 189–200 [26,27]
HDL cholesterol (mg/dL) 48–55 46–48 39–45 [26,27]
LDL cholesterol (mg/dL) 120–121 126–129 121–126 [26,27]
Triglycerides (mg/dL) 86–111 93–126 120–147 [26,27]
hs-CRP (mg/L) 1.4–2.1 2.4–3.4 4.0–4.5 [26,27]
esRAGE (ng/mL) 0.52 ± 0.26 0.32 ± 0.18 0.3 ± 0.19 [26]
S100A12 (ng/mL) 5.35 ± 3.38 7.13 ± 5.4 8.41 ± 4.44 [26]
Adiponectin (µg/mL) 9.52 ± 0.49 6.15 ± 0.49 6.57 ± 0.457 [28]
IL-6 (pg/mL) 1.77 ± 0.23 2.00 ± 0.14 2.84 ± 0.62 [29]






White blood cell (103/µL) 6.4 ± 1.6 7.1 ± 1.8 7.2 ± 1.8 [26]





Pulse wave velocity (m/sec) 7.1 ± 1.7 7.6 ± 1.6 8.6 ± 1.7 [26]
Coronary plaque progression
(odds ratio) - 1.338 1.635 [32]
Coronary artery calcification
(odds ratio) - 1.253 2.215 [33]
Atherosclerotic cardiovascular
disease events (%) 14.24 17.81 30.40 [27]
HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein;
esRAGE, endogenous secretory advanced glycation end-products; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
3. Prediabetes Affecting Monocyte and Macrophage Activities That Lead to
Atherosclerosis
For the progression of atherosclerosis, it is critical for the recruited monocytes to
engulf LDL accumulated under the surface layer of blood vessels [34]. Hyperlipidemia in
DM is known to increase the number of circulating neutrophils and monocytes through
myelopoiesis [35].
Interestingly, Flynn et al. reported that even in the absence of DM or insulin resistance,
the change in glucose level activated the bone marrow, leading to mononucleosis and
accelerating atherosclerosis [36]. Meanwhile, transient intermittent hyperglycemia (TIH)
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caused hematopoietic stem and progenitor cells (HSPC) to proliferate and differentiate
in the bone marrow, leading to a rapid expansion of common myeloid and granulocyte-
macrophage progenitors and a subsequent white blood cell proliferation. In particular, TIH
caused the proliferation of Ly6Chi mononuclear cells, which induce atherosclerosis more
strongly than other monocytes. According to Graubardt et al., removing the circulating
Ly6Chi monocytes reduces neutrophils that produce reactive oxygen species (ROS) [37],
which is one of the critical factors of both DM and atherosclerosis [38]. Other risk factors
found in prediabetic obesity, such as inflammation, dyslipidemia, oxidative stress, and
signal transduction from adipose tissue macrophages, may also promote the expansion
and differentiation of bone marrow HSPCs and, subsequently, leukocytosis [39–41].
On the other hand, glucose uptake by neutrophils after TIH is vital for driving
CVDs [42,43]. Glucose transporter 1 (GLUT-1) is involved in glucose uptake; myeloid-
restricted GLUT-1 deletion reduces glucose uptake by neutrophils and prevents TIH-
induced myelopoiesis and atherosclerosis [36,43]. Flynn et al. found that when the glucose
level is too high, neutrophils quickly reach their maximum glycolysis rate, leading to
ROS production and protein kinase C (PKC) activation, which triggers the release of S100
calcium-binding proteins A8 and A9 (S100A8/A9). The release of S100A8/A9 initiates
bone marrow production. S100A8/A9 proteins account for 40% of the neutrophil cytoplas-
mic protein, which is released upon inflammation and stimulates leukocyte recruitment,
and it induces cytokine secretion [44,45]. S100A8/A9 is also upstream of the receptor for
advanced glycation end-products (RAGE) signaling. The RAGE pathway plays a crucial
role in hyperglycemia-induced myelopoiesis and TIH-induced mononucleosis. Koulis et al.
discovered that RAGE mediation plays a vital role after a brief increase in blood sugar in
atherosclerosis [46].
Another calcium-binding protein, S100A12, alias extracellular newly identified RAGE
binding protein, is found in high concentrations in the blood of prediabetes and dia-
betes [26] (Table 1). As it facilitates the expression of adhesion molecules in the endothelial
cells and the resulting migration of monocytes and macrophages, it is regarded as a pro-
atherosclerotic factor [47]. Furthermore, the blood level of endogenously secreted RAGE,
which can contribute to the neutralization of circulating RAGE ligands, is decreased in
prediabetes [26]. This further facilitates the development of atherosclerosis. Therefore,
targeting the RAGE pathway may be essential in eliminating hyperglycemia-induced
atherosclerosis.
4. Relationship between Diabetes and Endothelial Dysfunction
While monocytes and macrophages differ in their roles in the pathogenesis of atheroscle-
rosis, a loss of endothelial function is another factor that causes atherosclerosis. In the earliest
stages of obesity, the endothelial function begins to be impaired.
4.1. Disrupted Endothelial Network Signaling in Prediabetes
Endothelial cells had long been considered a uniform cell group. However, it recently
became clear that they have mosaic-like populations that respond differently and form
a network to transmit information to change vascular permeability and perform remod-
eling functions [48]. The endothelial function manages the vascular function through
multicellular network Ca2+ dynamics and the cellular heterogeneity [49].
Endothelial-dependent vasodilation is caused by network-level interactions between
endothelial cell populations, and the prediabetic obesity’s control of this network-level
can be damaged. Obesity changes the network activity and decreases the cell populations
that respond to acetylcholine, causing vasodilation, increasing sensory cell clusters, and
lengthening the distance for information transmission between cell clusters. For example,
Wilson et al. demonstrated that communication between endothelial cells is disrupted in
rats with prediabetic obesity [50]. They found that obesity impaired the calcium response
in the endothelial cell network, leading to insufficient endothelial vascular tone control.
Int. J. Mol. Sci. 2021, 22, 4108 5 of 15
Multiple molecular mechanisms may cause abnormal vasodilation in prediabetes. The
increase of ROS inactivates endothelial nitric oxide (NO), thus decreasing vasodilation
in obese animals [51,52]. The potassium channel activity [53,54], NO release [54], or the
regulation of endothelial function induced by the adipose tissue [55,56] may also lead to
the impairment of endothelium-dependent vasodilation in obesity.
In summary, the decline in vascular function seen in prediabetes is due to abnormal
signaling in the disrupted network of vascular endothelial cells, which may contribute to
the development of atherosclerosis. These findings provide a new approach to analyze the
vascular dysfunction in prediabetic obesity.
4.2. Endothelial Damage Induced by Microparticles
As early as 2010, researchers have discovered that microparticles (or submicron mem-
brane vesicles) that are shed from the cellular plasma membrane are involved in endothelial
damages that lead to atherosclerosis [57,58]. Moreover, Jansen et al. analyzed the circulat-
ing endothelial microparticles (EMP) produced by human coronary artery endothelial cells
(HCAEC) at high concentrations of glucose. These EMPs were defined as “wounded” cir-
culating endothelial microparticles (iEMP) and produced by “healthy” untreated HCAEC.
Jansen et al. found that iEMP increased the activity of the ROS-producing NADPH oxidase;
therefore, iEMP contained higher levels of ROS than EMP. iEMP triggered the phosphoryla-
tion of activating p38, a protein involved in apoptosis, in a manner depended on ROS. High
glucose conditions could activate NADPH oxidase in EMPs, thereby exacerbating endothe-
lial inflammation and impairing endothelial function. The microparticle-related endothelial
damage and the impaired signaling of the endothelial network provide a framework to
understand how endothelial cell damage exacerbates atherosclerosis in prediabetes.
4.3. Endothelial Dysfunction and Inflammation Increase
In 2016, researchers used enzyme-linked immunosorbent assays to analyze the levels
of intercellular adhesion molecule-1 (ICAM-1), TNF-α, P-selection, and IL-6 in the serum
of prediabetic patients. These markers are regarded as indicators of endothelial function
and inflammation. The study results showed that the above four markers in patients
with prediabetes were significantly higher than those in healthy subjects. Therefore, this
suggested that prediabetes induces endothelial dysfunction and inflammation by increasing
the levels of soluble adhesion molecules and inflammatory cytokines [59].
In addition, another study also explored endothelial dysfunction in diabetic patients.
Researchers used the I-arginine test to compare the endothelial function and to measure
the levels of TNF-α between healthy subjects and patients with prediabetes after a high-fat
diet. This demonstrated that after a high-fat intake, the triglyceride and TNF-α levels in
patients with prediabetes increased more than those without diabetes, and the endothelial
function of diabetic patients was also reduced significantly [60].
Sardu et al. conducted clinical studies on the effects of biguanide treatment on
reducing coronary endothelial dysfunction. The results showed that the percentage of
endothelial dysfunction of the left anterior descending coronary artery (LAD) in patients
with normal blood glucose was lower than that in patients with prediabetes. Following
biguanide (metformin) application, the endothelial LAD dysfunction in patients with
prediabetes was clearly eased compared with that in patients who had not been treated
with biguanide. Furthermore, the incidence of adverse cardiovascular events was much
higher in patients with prediabetes without biguanide treatment. Therefore, this indicates
that biguanide application could reduce coronary endothelial dysfunction and decrease
the risk of adverse cardiovascular events in prediabetes patients [61].
Current studies have shown that adiponectin’s serum level is related to coronary
artery stenosis caused by impaired endothelial function [62,63]. Inhibition of adiponectin
may lead to diabetes [64], obesity [65], atherosclerosis [66], and metabolic syndrome [18].
Ferdinando Carlo Sasso et al. conducted an observational study on the relationship between
adiponectin, insulin resistance, and ischemic heart disease (IHD) in subjects with normal
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glucose tolerance [67]. This study performed an oral glucose tolerance test with subjects
who have a history of diabetes or with impaired fasting blood glucose levels [67]. The
scientists evaluated the relationship between adiponectin and insulin resistance and the
occurrence of restenosis in these subjects, and findings showed that the level of adiponectin
was directly related to the occurrence of restenosis [67]. In contrast, insulin resistance and
adiponectin were independently associated with ischemic heart disease [67]. This study
found that insulin resistance and adiponectin affected IHD at any stage in subjects with
normal glucose tolerance [67].
5. Prediabetes-Facilitated Extracellular Vesicles Release in Atherosclerosis
Extracellular vesicles, which are spherical objects formed by exfoliation of cell mem-
branes, consist of submicron-sized microparticles and nanometer-sized exosomes [68,69].
They affect the behavior of distant target cells, and in recent years they have generated
much research interest [70–72]. The exosomes are involved in the pathogenesis of DM,
including, specifically, insulin resistance [73]. Moreover, exosomes have been found to
cause CVDs in diabetic conditions [74,75].
5.1. Platelet-Derived Microparticles in Prediabetic Patients
In 1993, Nomura et al. reported that platelets were activated and the concentration of
plasma platelet-derived microparticles increased in patients with diabetes. Interestingly,
a correlation was observed between the fasting blood glucose levels and the presence of
platelet-derived microparticles [76]. Moreover, researchers found an association between
the number of platelet-derived microparticles and the levels of LDL and triglycerides [77];
it was found that high levels of LDL and triglycerides are present in the development of
atherosclerosis.
In 2014, Zhang et al. investigated the circulating microparticle concentrations from
platelets, white blood cells, and monocytes in obese subjects and type 2 DM patients [78],
and they found that the plasma concentration of platelet microparticle increased in type 2
DM patients regardless of their weight. Overall, these findings imply that a high level of
blood glucose activates platelets and facilitates the release of platelet-derived microparticles,
leading to the development of atherosclerosis.
5.2. CD36 Expressed in Platelets and Macrophages
CD36, initially characterized as a scavenger receptor at the platelet membrane that
takes up lipoproteins, is involved in the pathogenesis of atherosclerosis [79,80]. CD36 is
also expressed in macrophages and induces their transformation into foam cells, forming
atherosclerotic plaques through their scavenging of oxidized LDLs [81] (Figure 1). Interest-
ingly, Handberg et al. found a soluble form of CD36 in plasma and that the level of the
plasma CD36 was correlated with fasting plasma glucose levels in type 2 DM patients [81].
Furthermore, according to Lopez-Carmona et al., CD36 is overexpressed in monocytes in
atherosclerotic patients [82]. Another study indicated that circulating exosomes express
functional CD36 and that the amount of exosomal CD36 increases in the postprandial
state. Garcia et al. suggested that the circulating exosomes deliver free fatty acid in the
bloodstream to cardiac tissue through an uptake via CD36 [83].
In summary, CD36, associated with prediabetes and atherosclerosis, is expressed at the
cellular membranes of platelets and macrophages, in a soluble form, or exosomes. While
CD36’s involvement in the pathogenesis of arteriosclerosis must be addressed in future
research, its exosomal form can act as a marker for prediabetes and atherosclerosis.
5.3. CD105 Expression in Atherosclerosis and Prediabetes
Endoglin, also known as CD105, is a transmembrane glycoprotein mainly expressed
on endothelial cells; it functions as a co-receptor for the transforming growth factor beta
(TGF-β) [84]. In 2000, Bethell et al. reported the increased level of CD105 in the serum from
atherosclerotic patients [85]. Later, Chironi et al. found that the thickness of intima-media
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in the common carotid artery was correlated with the increased level of CD105-expressing
circulating microparticles, even before atherosclerosis was detectable [86].
In searching for the source of the microparticles expressing CD105 during the devel-
opment of atherosclerosis, multiple research groups have identified cells with an unstable,
vulnerable atherosclerotic plaque expressing CD105 [87–89]. During the development of
atherosclerotic plaques, it was found that vasculature invades into the plaques. CD105
expression is associated with angiogenesis or neovascularization, where endothelial cells be-
come activated and proliferate [90] (Figure 1). According to Luque et al., CD105 expression
is associated with angiogenesis during the development of atheroma, but not necessarily
with the atherosclerotic plaque itself [91]. CD105 expression was also observed in smooth
muscle cells and macrophages in aortic atherosclerotic regions [92]. Therefore, the increase
in CD105-expressing circulating microparticles during the progression of arteriosclerosis is
likely due to their release from cells, especially endothelial, in atherosclerotic plaques.
Recent research has discovered that physical exercise affects the type and amount
of extracellular vesicles in circulation [93,94]. Interestingly, Eichner et al. reported that
interval exercise lowered the level of circulating extracellular vesicles expressing CD105
in prediabetic patients [95]. It is tempting to hypothesize that fitness prevents the devel-
opment of atherosclerosis by reducing the number of circulating extracellular vesicles
expressing CD105. However, the hypothesized involvement of CD105 in the development
of atherosclerosis in prediabetes must be further investigated.
6. The Involvement of miRNAs in the Pathogenesis of Prediabetes and
Atherosclerosis
In the previous section, we discussed the identification of extracellular vesicles express
surface markers, such as CD36 and CD105, in prediabetic patients. These vesicles are
likely involved in the development of atherosclerosis. CD36 is actively involved in fatty
acid transport in macrophages. In addition to containing functional surface proteins,
extracellular vesicles transport miRNAs in the bloodstream [96]. While some miRNAs are
transported in an encapsulated form in vesicles, most miRNAs maintain their stability
by forming a complex with other proteins during the transport in the bloodstream. This
section discusses the mechanisms of miRNAs’ possible involvement in the pathogenesis of
prediabetes and atherosclerosis.
6.1. Macrophage miRNAs Reducing the Production of Myeloid Cells and Suppressing
Inflammation in Atheroma
Specific kinds of miRNAs induce anti-inflammatory effects. For example, the anti-
inflammatory effect of miR-146b has been reported in a sepsis disease model and pneu-
monia [97,98]. In addition, miR-146b was reported to reduce inflammation via TRAF-6,
a signal transducer in the NF-κB pathway, in a hypercholesterolemic condition that leads
to atherosclerosis [99]. The expression level of miR-146b has been associated with HbA1c,
a marker for high blood sugar level maintained over weeks/months [100]. Consistent
with this finding, miR-146a expression is higher in DM patients than in prediabetic pa-
tients [101]. On the other hand, miR-99a, an anti-inflammatory miRNA, inhibits the
production of inflammatory mediators, such as TNF-α, IL-6, IL-1β, and MCP-1 [102]. More-
over, the IL4-driven anti-inflammatory effects of miR-378a on macrophages have been
suggested [103].
Interestingly, Bouchareychas et al. reported that macrophage exosomes ameliorated
atherosclerosis by regulating hematopoiesis in the bone marrow and inflammation in
atheroma through miRNA [104]. Mainly, the exosomes generated from naive bone marrow-
derived macrophages (BMDM) contained anti-inflammatory miR-99a, miR-146b, and miR-
378a [104]. It was found that exposure of IL-4 to BMDMs further facilitated the production
of exosomes containing the anti-inflammatory microRNAs. These exosomal microRNAs
inhibited the inflammation in atheroma by aiming at NF-κB and TNF-α signaling. Fur-
thermore, the infusion of exosomes from IL-4 activated BMDM into mice can reduce
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hematopoiesis in bone marrow, thereby reducing both the number of macrophages in aortic
root lesions and the number of atherosclerotic necrotic lesions.
The discovery that atherosclerosis development can be suppressed by exosomes
containing miRNAs is quite sensational. Additionally, the high expression level of miR-
146b in DM patients suggests that an anti-inflammatory response had already occurred
in these patients. Thus, the administration of exosomes containing miR-99a and miR-
378a to suppress the progression of atherosclerosis or inflammation is an anticipated
clinical strategy.
6.2. Prediabetes Altering Expression of miRNAs in the Heart
Éva Sághy et al. found that prediabetes alters the expression of specific miRNAs
that subsequently modulate their corresponding target mRNAs’ expression in the left
ventricles of rats [105]. This study also found that miR-141 and miR-200c were upregulated,
and that miR-200a, miR-208b, and miR-293 were downregulated in prediabetic patients.
The authors predicted their target mRNAs computationally from the sequences of these
miRNAs. They then verified the down-regulation of three mRNAs, i.e., the juxtaposed
with another zinc finger protein 1 (JAZF1), Rap2c of the RAS oncogene family, and zinc
fingers with KRAB and SCAN domain 1 (ZKSCAN1). The miRNAs were isolated from
homogenized ventricular tissue in this study. Therefore, it is necessary to investigate the
origin of the detected miRNAs. It would also be interesting to see whether exosomes
containing these miRNAs are released into the bloodstream. While the miRNAs may be
released from noncardiomyocytes, such as cardiac fibroblasts or vascular endothelial cells,
some studies suggested that cardiomyocytes secrete the exosomes, and that the effect of
the exosomes is derived from miRNAs [106].
As mentioned above, JAZF1 is one of the genes downregulated by miRNA in pre-
diabetic patients. JAZF1 is a transcriptional cofactor involved in gluconeogenesis, lipid
metabolism, and insulin resistance; it is related to JAZF1 expression in type 2 DM [107,108].
According to Li et al., JAZF1 prevents atherosclerosis by reducing the number of atheroscle-
rotic plaques in the aortic sinus [107]. Therefore, the decreased expression of JAZF1 in
prediabetes may be associated with the development of atherosclerosis.
6.3. miR-483 Causing Lipotoxicity, Insulin Resistance, and Impaired Endothelial Integrity
What we eat in the early stages of development affects the subsequent development
of diabetes and atherosclerosis. Even more remarkably, the expression of a specific miRNA
provides this effect. miR-483 can be partially mediated by the translational growth inhibi-
tion/differentiation factor 3. It can also regulate the adipocytes’ ability to differentiate and
store lipids [109]. Partially mediated by translational growth inhibition/differentiation fac-
tor 3, a target of miR-483, miR-483 regulates the adipocytes’ ability to differentiate and store
lipids. In summary, early life nutrition induces an increase in miR-483 expression, which in
turn limits lipid storage in adipose tissue, causing lipotoxicity and insulin resistance and
increasing the risk of metabolic diseases.
In addition, miR-483’s expression level is higher in M2-type macrophages and in the
aortic wall of patients with type 2 DM [110]. Moreover, overexpressing miRNA-483 causes
endothelial apoptosis and impairs endothelial regeneration [110]. Furthermore, serum
miR-483 level is associated with DM and CVD [111]. It would be interesting to identify
the tissue that causes the elevation of serum miR-483 and to examine whether the events
occurring in endothelial cells and adipose tissue are associated with serum miR-483. In
summary, excessive nutrition during early development may cause the upregulation of
miR-483, leading to impaired endothelial integrity and subsequent CVDs. These possible
effects of miR-483 upregulation should be examined in future studies.
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7. Association between Prediabetes and Risk of Mortality Induced by CVD
Tang et al. compared the CVD-associated mortality between patients with prediabetes
or those with diabetes. They found that there was no significant correlation between the
risk of mortality from prediabetes and that of newly diagnosed diabetes. Patients with
long-term diabetes were found to be at a high risk of mortality caused by CVD. Accordingly,
the report suggested that in the elderly, long-term diabetes would lead to an increase in
short-term mortality. The study also showed that at a median follow-up of 5.6 years, elderly
people with prediabetes were still at a lower risk of death [112].
Additionally, Cai et al. investigated the association between prediabetes and the
mortality and risk of CVD through a meta-analysis according to the Epidemiological Obser-
vational Research (MOOSE) group [113]. In this study, the authors found that prediabetes
could increase mortality in patients with CVD or atherosclerotic heart disease [114]. More-
over, this study also showed that the risk of coronary heart disease and stroke would
be higher in people with impaired glucose tolerance; the fasting blood glucose concen-
tration for deaths caused by impaired fasting blood glycemia was 6.1–6.9 mmol/L [114].
Hence, this finding identified that prediabetes leads to an increase in mortality caused by
cardiovascular disease.
8. Intervention and Treatment of Prediabetes
Prediabetes is a risk factor of T2DM and is also related to cardiovascular disease, so
early interventions and treatments are critical [115]. Currently, lifestyle interventions, such
as diet and exercise, are the preferred options [116,117]. In addition, medical therapy, such
as treatment with biguanides (metformin), α-glucosidase inhibitors (acarbose), pancreatic
lipase inhibitors (orlistat), PPAR-γ agonists (rosiglitazone, pioglitazone), and metatinib
(nateglinide), is also extensively used to cure prediabetes [117,118]. Bariatric surgery is also
suitable for patients with prediabetes who are also obese [119]. In 2019, scholars in the UK
proposed that prediabetes treatment should be personalized according to the predictable
phenotype’s specificity, and that interventions corresponding to that phenotype should be
used. They suggested that knowledge of the phenotype’s specific pathophysiology may
increase the value of funding appropriate treatments for patients with prediabetes [117].
This proposal provides new feasibility for intervention treatments for prediabetes patients
and may optimize previous treatment plans.
9. Conclusions
Increasing attention is focused on understanding the mechanism that causes CVDs in
prediabetes. As discussed above, hyperglycemia was found to cause increased hematopoiesis
and ROS-producing neutrophils, leading to atherosclerosis development during predia-
betes. These mechanisms were discussed in detail by Naoto Katakami in his review [120].
We further discussed the involvement of extracellular vesicles and miRNAs in the de-
velopment of atherosclerosis in prediabetes. Hyperglycemia facilitates the production of
extracellular vesicles from numerous types of cells, including vascular endothelial cells
and leukocytes. These extracellular vesicles, including exosomes, facilitate atherosclerosis
via specific proteins, such as ROS-producing NADPH oxidase and LDL-scavenging CD36.
The extracellular vesicles also carry specific kinds of miRNAs that facilitate atherosclerosis
by hematopoiesis and promoting inflammation.
The abovementioned functional proteins, miRNAs, and extracellular vesicles that
transport miRNAs are highly anticipated targets for preventing or treating the development
of atherosclerosis in prediabetes. On the other hand, it gives us hope that improving habits,
such as diet and exercise, can suppress prediabetes and atherosclerosis via specific cellular
mechanisms. In this era of increasingly prevalent prediabetes, further research in this area
will contribute to the health of many.
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